Home > Boards > US OTC > Medical - Equipment >

Zenosense, Inc. (ZENO)

Add ZENO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/11/2022 12:30:04 PM - Followers: 33 - Board type: Free - Posts Today: 0

NEWS JUNE17! Yahoo Finance: Zenosense, Inc. ( OTC PINK : ZENO ) has received notice of a patent issuance in the U.S.

YTD: 266%
1 Year: 141%


ZenoSense (OTC:ZENO) has carved out a unique space in a revolutionary new biomedical field that is forecast to grow to $7.2 billion in the next year. ZENO is on the vanguard of this rapid growth because it’s focusing on a disease that claims the lives of 1 in 4 Americans.(1)

About Zenosense
The Revolution In Cardiac Diagnostics

Laboratory accuracy testing in the palm of your hand -
Taking diagnosis to a new, super-sensitive, nano-magnetic level

Zenosense, Inc. (OTC:ZENO) participates in the development of transformational medical diagnostic technologies: hand-held devices used at the Point of Care replacing slow and expensive laboratory testing. Our core focus through our joint venture in MIDS Medical (http://midsmed.com/) is the development and commercialisation of MIDS Cardiac™. A hand held device being developed for use at the Point of Care for the rapid testing of cardiac markers delivering results equal or superior to laboratory gold standard accuracy within minutes. A device which can revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI).

Our team of professionals has world class expertise and technical know-how of the application of highly specific nano magnetic particle technology to medical testing.  This knowledge, alongside their commercial experience of the Point of Care market, puts MIDS Medical in an excellent position to commercialise MIDS Cardiac™ and become the leading innovator in this field.

The MIDS Medical laboratory is located at the prestigious, UK Government supported Sci-Tech Daresbury campus in the UK. Sci-Tech Daresbury is internationally recognised for leading-edge scientific research and commercial development.

Good to know
Cardiovascular disease is the leading cause of death in the Western World. Accounting for more than 17 million deaths p.a. In Europe and the US alone approximately 15-20 million patients a year visit an Emergency Department (ED) reporting chest pain which must be investigated as possibly caused by a cardiac event. Every 43 seconds someone in the US has a heart attack.

Acute Myocardial Infarction (heart attack, Acute Myocardial Infraction “AMI”) affects all of us at some point in our lives, directly or indirectly, Rapid diagnosis is key; treatment in the first “Golden Hour” being crucial to survival. Equally, early “rule out” of AMI as  the cause of chest pain can save healthcare providers $billions.

Through our Joint Venture ownership in MIDS Medical we are developing MIDS Cardiac™, a cost-effective hand held Point of Care rapid cardiac diagnostic device. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and world-class technical expertise.

Our development targets the delivery of a hand held device to support high sensitivity tests to identify or discount AMI (Heart Attack), with accuracy equal or better than gold standard laboratory tests, within minutes. This will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected Acute Myocardial Infarction.

The system is designed to be used with a minimum of training; by any ER nurse or by paramedics at the scene. We believe such a device will be in universal demand; able to meet a critical medical need and rapidly penetrate a multi-billion dollar market.

MIDS Cardiac(TM)
Rapid detection of very low levels of cardiac markers with a primary focus on troponin I and T, designed to equal or exceed gold standard laboratory levels of accuracy, at the Point of Care.

>> Proof of Market (PDF) <<

Investment Highlights

  • Addressing Lethal Global Health Threat
    Co-Developing Unique Detection Device
    Strong Partnership with Sgenia Group
    Experienced, Strong Management
    Team of Highly Qualified Biologists

Key Partnership

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through its subsidiary, Zenon Biosystem. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors." The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Sgenia Group, known for sensor development and a supplier of sensors used in the Tokamak device for a significant, international nuclear fusion research project, also produces an algal contamination detector for use in water supply applications. It rapidly and effectively scans for the volatile organic compounds (VOCs) emitted by the target algae, a unique “chemical signature” that determines the presence or absence of the algae. The Sgenia detector is effectively an electronic “nose” that can smell this signature.

Zenon is using essential elements of these technology platforms in a development program for the MRSA/SA device to be developed for Zenosense.


Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors.

Carlos Jose Gil, BSc (Engineering) - President, CEO, CFO

Carlos Jose Gil joined the company in October 2013 as a member of the board. He has experience in high-level sales management and the development of sales teams in the health care sector. From 2012 to 2013, Gil served as a managing director of Porsche Car Spain. From 2009 to 2012, Gil was sales manager at Pharmaceutic Laboratory PersanFarma. From 1994 to 2009, Gil was a medical consultant in Medical Affairs and then an account manager at Pharmaceutic Laboratory Janssen-Cilag (Johnson & Johnson). Gil holds a Bachelor of Science in Chemical Science from Valencia University, Spain.

Development Team

J. Lama, MBA, BSc

J. Lama is an engineer with a Master of Business Administration and a Bachelor of Science (Physics). His experience includes material engineering, solid state physics, electronics, renewable energy, the automotive industry and developing technological business.

M. Querol, MS

M. Querol is a mechanical engineer with a Master of Science in Telecommunications Engineering. His experience includes market development of global solutions for Aeronautical, Naval and Defense sectors, market development of internalization strategy development, and market development of industrial engineering solutions.

M. I. Gil, DEA, BSc

M. I. Gil has a Master of Advanced Studies in Fluids Mechanics from Centro Politecnico Superior of University of Zaragoza in Spain, as well as a Bachelor of Telecommunication Engineering. Gil has wide experience in sensor technologies and advanced technical and software developing.

G. Roman Perez, PhD, MAS, BSc

G. Roman Perez has a PhD in physics from the Autonomous University of Madrid (UAM), with Cum Laude distinction. He also has a Master of Advanced Studies in Condensed Matter Physics, a Master of Biophysics and a Bachelor of Physics, all issued by UAM. His work has been published in several different publications and he has spoken at conferences in France, Italy, Spain and the USA.


The company will also rely upon a team of three biologists contracted to Zenon for the development of the Sgenia Products. This team is comprised of molecular biologists and biochemists specializing in bacterial physiology and genetics, clinical microbiology and molecular biology. All hold relevant PhDs, and two hold Masters, in disciplines highly relevant to optimizing the company’s sensor for the detection of MRSA/SA. The team’s combined skillset includes deep knowledge of the clinical genetics to be addressed in order to program and refine the sensor so that it can detect SA and ideally discriminate between MRSA and SA. Variously, members of the team are business (biotechnology) management qualified, have co-authored numerous scientific publications, taught as professor, have experience of the practical clinical setting in hospital and have co-invented patents for others.

Zenosense, Inc.
Avda Cortes Valencianas 58
Planta 5 46015
Valencia, Spain
Phone: 34-96-045-4202


QualityStocks designed this iBox. Please see disclaimers on the QualityStocks website: http://qualitystocks.net/disclaimer.php

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZENO News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 04/01/2019 03:00:54 PM
ZENO News: Quarterly Report (10-q) 11/14/2018 05:13:15 PM
ZENO News: Zenosense, Inc.: MIDS Medical Expands Technical Team 10/02/2018 07:42:11 AM
ZENO News: Zenosense, Inc.: MIDS Medical JV to Receive Funding of Up to $1.2 Million 09/05/2018 08:00:44 AM
ZENO News: Current Report Filing (8-k) 09/04/2018 05:14:08 PM
#1278   David Lazar is a custodian. There is an PennyStaIker 01/11/22 12:30:04 PM
#1277   Who is Lazar? And do you have link? McMagyar 12/24/21 10:08:56 AM
#1276   Not much dollar amount in the volume. rtrstock 11/04/21 12:22:17 AM
#1275   Lazar filed petition for custodianship yesterday. PennyStaIker 11/03/21 12:17:48 PM
#1274   Not planning on investing in this but why Sade123 11/03/21 12:16:51 PM
#1273   This thing is dead eh? Mbrady4 04/01/21 10:30:37 AM
#1272   Why not read it? janice shell 01/08/21 04:36:17 PM
#1271   What does this have to do with Zeno? McMagyar 01/08/21 04:33:58 PM
#1270   Criminals! Mbrady4 02/12/20 08:55:18 AM
#1269   Sort of. See this SEC-DOJ action: janice shell 01/02/20 05:07:08 PM
#1268   Any new info here??? Mbrady4 11/01/19 12:57:42 PM
#1267   Man this is done. Fork in her. That’s AW104 08/22/19 10:43:31 PM
#1266   News coming I wonder. Trading up so leak stockmule 08/14/19 10:55:04 AM
#1265   Guess we have a giant nothing here. No AW104 07/01/19 10:28:10 PM
#1264   Tight lower channel. It seems all selling is AW104 04/05/19 12:05:01 PM
#1263   Shady company Las_Vegas 03/29/19 01:25:34 AM
#1262   Just look at trades : they all sells Las_Vegas 03/29/19 01:24:45 AM
#1261   News: $ZENO Zenosense, Inc.: Update on MIDS Medical whytestocks 03/20/19 11:30:45 AM
#1260   https://www.globenewswire.com/news-release/2019/03/20/1757660/0/en/Zenosense-Inc AW104 03/20/19 08:46:21 AM
#1259   Looks like based on today’s news the prototyping derkampfer 03/20/19 08:38:34 AM
#1258   It will if we get news on MIDS. derkampfer 03/09/19 10:30:57 AM
#1257   Exactly. AW104 03/01/19 12:33:31 PM
#1256   being mentioned in a complaint vs being the dinoshark 03/01/19 09:39:42 AM
#1255   ZENO has been named by the SEC as elkonig 02/27/19 12:21:56 AM
#1254   Looks like somebody is accumulating. Last 30 days. AW104 02/26/19 12:29:09 AM
#1253   Yup. They’re in violation of missed SEC filings. derkampfer 02/06/19 04:14:08 PM
#1252   Bottom line Tom Barr has screwed his BIA* carp1 02/06/19 12:17:46 PM
#1251   Think a rebound @.12 Fres 02/01/19 07:26:10 AM
#1250   52 week low about to hit. The last AW104 01/29/19 04:01:49 PM
#1249   Eat grass Las_Vegas 01/28/19 02:19:54 PM
#1248   Whatever jackazz. Your senseless driveling is just that. derkampfer 01/27/19 06:52:13 PM
#1247   Btw you are the only Mohican left on Las_Vegas 01/27/19 10:55:10 AM
#1246   It’s 100% scam , no matter the way Las_Vegas 01/27/19 10:53:59 AM
#1245   So Bio-AMD and the 60/40 MML partnership and derkampfer 01/27/19 01:38:52 AM
#1244   Stupid is you to invest in scam The pump Las_Vegas 01/27/19 12:37:56 AM
#1243   Ok enjoy your stupidity derkampfer 01/26/19 03:10:51 AM
#1242   Ok enjoy your bags Las_Vegas 01/25/19 04:23:53 PM
#1241   I know what they do. I’ve been to derkampfer 01/21/19 03:23:09 AM
#1240   Zenosense, Inc. engages in developing medical devices. It Las_Vegas 01/20/19 10:21:03 PM
#1239   Been to Daresbury. You? derkampfer 01/19/19 12:17:21 AM
#1238   You sure? Did you visit their office ?? Hehe Las_Vegas 01/18/19 01:03:41 AM
#1237   It’s not a pump. They make good progress derkampfer 01/11/19 03:34:30 PM
#1236   Sleeping before the next move? Seems like the AW104 01/11/19 01:56:22 PM
#1235   Yeah but being mentioned in a complaint vs AW104 11/01/18 10:23:55 PM
#1234   Thats because ZENO is mentioned in an SEC elkonig 11/01/18 05:24:04 PM
#1233   Volume dropping 0 this morning. Low volume=low interest. lt2211 10/24/18 09:45:14 AM
#1232   Maybe it’ll hit tomorrow? Seems like we’re trading AW104 10/02/18 10:33:57 PM
#1231   NEWS OUT! Zenosense, Inc.: MIDS Medical Expands Technical Team hotstockpicker 10/02/18 08:27:05 AM
#1230   Any word on what’s happening here? Seems like AW104 09/20/18 11:10:00 PM
#1229   Soon to be saving lives and selling DOLLARS ! GrabThatCash 09/05/18 05:06:28 PM
Consent Preferences